EUCTR2004-000035-28-GB进行中（未招募）不适用
TDS-943 MAXIMUM USE TOLERANCE STUDY
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subject is cleared by a site-affiliated physician.
- •- Females are not pregnant or breast feeding.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
- •- Subject is cleared by a site-affiliated physician.
- •- Females are not pregnant or breast feeding.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- history of any hypersensitivity (including asthma, rhinitis, or urticaria) to diclofenac
- •or to any of the excipients used in the topical spray, or to aspirin or any other NSAID, or to paracetamol;
- •- on chronic nonsteroidal anti-inflammatory drug therapy, defined as taking a daily
- •regimen 5 to 7 days/week;
- •- history (within the past 2 years) of a cutaneous reaction to any pharmaceutical
- •or non-pharmaceutical product;
- •- history of any hypersensitivity (including asthma, rhinitis, or urticaria) to diclofenac
- •or to any of the excipients used in the topical spray, or to aspirin or any other NSAID, or to paracetamol;
- •- on chronic nonsteroidal anti-inflammatory drug therapy, defined as taking a daily
- •regimen 5 to 7 days/week;
- •- history (within the past 2 years) of a cutaneous reaction to any pharmaceutical
- •or non-pharmaceutical product;
研究者
相似试验
进行中（未招募）
不适用
A Safety Study of TDS-943Of Product: Relieve pain and swelling in joints, musclesEUCTR2004-001586-18-GBWyeth Consumer Healthcare75
进行中（未招募）
不适用
Phase I Study to Determine the Maximum Tolerated Dose of NC-6004 in Patients with Solid Tumours - Phase I dose-escalation Study of NC-6001 in patients with solid tumoursHistologically-confirmed advanced solid tumours for which no standard therapy exists or has failed therapyEUCTR2005-004827-20-GBanoCarrier Co., Ltd.30
进行中（未招募）
1 期
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersCystic FibrosisEUCTR2020-002251-38-DEVertex Pharmaceuticals Incorporated70
进行中（未招募）
1 期
A Phase III Study to Assess the Tolerability and Efficacy of MK-0822 (Odanacatib) in Reducing the Risk of Bone Metastases and Prolonging Disease-Free Survival in Women with Breast Cancer Spanish title: Estudio de Fase III para evaluar la tolerabilidad y eficacia de MK-0822 (Odanacatib) en la reducción del riesgo de desarrollar metástasis óseas y en la prolongación de la supervivencia libre de progresión en mujeres con cáncer de mama” - MK-0822 (Odanacatib) in Women with Breast CancerPrevention of disease recurrence in patients with breast cancer. Spanish indication: Prevención de recurrencia de la enfermedad en pacientes con cáncer de mamaMedDRA version: 9.1 Level: LLT Classification code 10005993 Term: Bone metastasesEUCTR2008-002119-42-ESMerck& Co., Inc.4,000
进行中（未招募）
1 期
A Phase III Study to Assess the Tolerability and Efficacy of MK-0822 (Odanacatib) in Reducing the Risk of Bone Metastases and Prolonging Disease-Free Survival in Women with Breast Cancer - MK-0822 (Odanacatib) in Women with Breast CancerPrevention of disease recurrence in patients with breast cancer.MedDRA version: 9.1Level: LLTClassification code 10005993Term: Bone metastasesEUCTR2008-002119-42-SKMerck& Co., Inc.4,000